Ashland's new profit target rests on an unfinished factory recovery

Ashland's strongest commercial programs brought in more sales than planned. Its manufacturing recovery remained uneven, while annual adjusted earnings per share fell from a year earlier.

That was not the finish management had forecast in July, when it still expected low-to-mid-single-digit growth in that measure. Ashland now enters a new fiscal year with a higher profit target and unfinished work at its Hopewell plant.

The company makes ingredients used in medicines, personal-care products, coatings and other applications. Better demand and product mix in pharmaceuticals and personal care helped its September quarter, while production problems held back Specialty Additives.

The recovery was uneven

Research by Ticker Byline shows that Ashland delivered the broad sequential profit improvement it expected in July, but the division containing Hopewell did not share in that recovery. Group adjusted EBITDA rose from $109 million in the June quarter to $121 million in September. Specialty Additives stayed at $20 million.

Compared with a year earlier, that division's adjusted EBITDA fell 31%. Ashland attributed the decline mainly to lower Hopewell productivity and the higher cost per unit that comes with running below capacity. It says critical investments are complete and the focus is now on increasing production.

Adjusted EBITDA measures earnings before interest, taxes, depreciation and amortization, with selected other costs removed. For the full year ended September 30, it was $385 million, meeting the bottom of July's $385 million to $400 million range.

The earnings-per-share outcome was weaker. Adjusted EPS excluding intangible amortization fell to $3.31 from $3.38, a decline of about 2%, against July's growth forecast. July's outlook had already been lowered because of unfavorable tax items. That measure also removes selected charges and tax items from continuing earnings.

The sales programs supplied a counterweight

Ashland's geographic expansion program generated $26 million of incremental annual sales against a $20 million target. Its innovation program also produced $26 million, ahead of a $15 million target.

In the September quarter, Life Sciences adjusted EBITDA rose 16% from a year earlier, while Personal Care increased 14%. Those gains helped group quarterly adjusted EBITDA rise 2%, despite the Specialty Additives setback.

Cash generation also improved. Annual operating cash flow from continuing operations was $385 million, up from $134 million. Ashland's ongoing free cash flow rose to $232 million from $127 million. That adjusted cash measure removes a previously received $103 million tax refund, while also adjusting receivables financing and selected cash costs.

A higher target needs more execution

For fiscal 2027, Ashland expects adjusted EBITDA of $405 million to $435 million. The midpoint is about 9% above the year just ended. Sales are forecast at $1.905 billion to $1.975 billion, compared with $1.863 billion. Planned capital spending rises to as much as $140 million from $88 million.

The plan calls for $10 million of net additional productivity benefits and $45 million of innovation-driven sales. It also assumes pricing will cover input-cost inflation, despite a stronger dollar reducing expected sales and profit.

The next results will show whether completed plant investments translate into more output and better margins alongside the commercial gains. The Ashland company profile tracks the earlier targets, current results and new financial plan.